Physician profile
Shae H Johnson
NPI 1669588315
$1,423.57
in general payments reported to CMS, 2019-2025
22 companies · $548 in 2025
The $548 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $88.48 · 2022: $22.59 · 2023: $119 · 2024: $412 · 2025: $548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,078.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $263.08 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $224.50 | 2019-2025 | |
| Abbvie INC. | $143.73 | 2024-2025 | |
| Dexcom, INC. | $128.72 | 2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $109.20 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $97.12 | 2019-2025 | Evenity, Prolia |
| Glaxosmithkline, LLC. | $84.99 | 2022-2024 | Arexvy |
| Sanofi Pasteur INC. | $64.18 | 2020-2025 | |
| Mylan Specialty L.P. | $34.60 | 2024 | Yupelri |
| Shield Therapeutics INC | $32.61 | 2024 | |
| Merck Sharp & Dohme LLC | $32.45 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $32.13 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $26.24 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.33 | 2019 | |
| Viatris Specialty LLC | $20.06 | 2025 | Yupelri |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $17.81 | 2025 | Mounjaro, Zepbound |
| Gilead Sciences, INC. | $17.56 | 2024 | |
| Amarin Pharma, INC. | $16.75 | 2020 | |
| Phathom Pharmaceuticals, INC. | $16.72 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $13.65 | 2019 | |
| Astellas Pharma US INC | $12.12 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shae Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.